Hypoactive Sexual Desire Disorder

Hypoactive Sexual Desire Disorder. Goldstein, I., Kim, N. N., Clayton, A. H., DeRogatis, L. R., Giraldi, A., Parish, S. J., Pfaus, J., Simon, J. A., Kingsberg, S. A., Meston, C., Stahl, S. M., Wallen, K., & Worsley, R. Mayo Clinic Proceedings, 92(1):114–128, January, 2017.

Paper doi abstract bibtex

The objective of the International Society for the Study of Women’s Sexual Health expert consensus panel was to develop a concise, clinically relevant, evidence-based review of the epidemiology, physiology, pathogenesis, diagnosis, and treatment of hypoactive sexual desire disorder (HSDD), a sexual dysfunction affecting approximately 10% of adult women. Etiologic factors include conditions or drugs that decrease brain dopamine, melanocortin, oxytocin, and norepinephrine levels and augment brain serotonin, endocannabinoid, prolactin, and opioid levels. Symptoms include lack or loss of motivation to participate in sexual activity due to absent or decreased spontaneous desire, sexual desire in response to erotic cues or stimulation, or ability to maintain desire or interest through sexual activity for at least 6 months, with accompanying distress. Treatment follows a biopsychosocial model and is guided by history and assessment of symptoms. Sex therapy has been the standard treatment, although there is a paucity of studies assessing efﬁcacy, except for mindfulness-based cognitive behavior therapy. Bupropion and buspirone may be considered off-label treatments for HSDD, despite limited safety and efﬁcacy data. Menopausal women with HSDD may beneﬁt from off-label testosterone treatment, as evidenced by multiple clinical trials reporting some efﬁcacy and short-term safety. Currently, ﬂibanserin is the only Food and Drug Administrationeapproved medication to treat premenopausal women with generalized acquired HSDD. Based on existing data, we hypothesize that all these therapies alter central inhibitory and excitatory pathways. In conclusion, HSDD signiﬁcantly affects quality of life in women and can effectively be managed by health care providers with appropriate assessments and individualized treatments.

@article{goldstein_hypoactive_2017,
	title = {Hypoactive {Sexual} {Desire} {Disorder}},
	volume = {92},
	issn = {00256196},
	url = {https://linkinghub.elsevier.com/retrieve/pii/S0025619616305961},
	doi = {10.1016/j.mayocp.2016.09.018},
	abstract = {The objective of the International Society for the Study of Women’s Sexual Health expert consensus panel was to develop a concise, clinically relevant, evidence-based review of the epidemiology, physiology, pathogenesis, diagnosis, and treatment of hypoactive sexual desire disorder (HSDD), a sexual dysfunction affecting approximately 10\% of adult women. Etiologic factors include conditions or drugs that decrease brain dopamine, melanocortin, oxytocin, and norepinephrine levels and augment brain serotonin, endocannabinoid, prolactin, and opioid levels. Symptoms include lack or loss of motivation to participate in sexual activity due to absent or decreased spontaneous desire, sexual desire in response to erotic cues or stimulation, or ability to maintain desire or interest through sexual activity for at least 6 months, with accompanying distress. Treatment follows a biopsychosocial model and is guided by history and assessment of symptoms. Sex therapy has been the standard treatment, although there is a paucity of studies assessing efﬁcacy, except for mindfulness-based cognitive behavior therapy. Bupropion and buspirone may be considered off-label treatments for HSDD, despite limited safety and efﬁcacy data. Menopausal women with HSDD may beneﬁt from off-label testosterone treatment, as evidenced by multiple clinical trials reporting some efﬁcacy and short-term safety. Currently, ﬂibanserin is the only Food and Drug Administrationeapproved medication to treat premenopausal women with generalized acquired HSDD. Based on existing data, we hypothesize that all these therapies alter central inhibitory and excitatory pathways. In conclusion, HSDD signiﬁcantly affects quality of life in women and can effectively be managed by health care providers with appropriate assessments and individualized treatments.},
	language = {en},
	number = {1},
	urldate = {2021-12-28},
	journal = {Mayo Clinic Proceedings},
	author = {Goldstein, Irwin and Kim, Noel N. and Clayton, Anita H. and DeRogatis, Leonard R. and Giraldi, Annamaria and Parish, Sharon J. and Pfaus, James and Simon, James A. and Kingsberg, Sheryl A. and Meston, Cindy and Stahl, Stephen M. and Wallen, Kim and Worsley, Roisin},
	month = jan,
	year = {2017},
	pages = {114--128},
}

Downloads: 0

{"_id":"D5ShWjGLh7s2k54Mw","bibbaseid":"goldstein-kim-clayton-derogatis-giraldi-parish-pfaus-simon-etal-hypoactivesexualdesiredisorder-2017","author_short":["Goldstein, I.","Kim, N. N.","Clayton, A. H.","DeRogatis, L. R.","Giraldi, A.","Parish, S. J.","Pfaus, J.","Simon, J. A.","Kingsberg, S. A.","Meston, C.","Stahl, S. M.","Wallen, K.","Worsley, R."],"bibdata":{"bibtype":"article","type":"article","title":"Hypoactive Sexual Desire Disorder","volume":"92","issn":"00256196","url":"https://linkinghub.elsevier.com/retrieve/pii/S0025619616305961","doi":"10.1016/j.mayocp.2016.09.018","abstract":"The objective of the International Society for the Study of Women’s Sexual Health expert consensus panel was to develop a concise, clinically relevant, evidence-based review of the epidemiology, physiology, pathogenesis, diagnosis, and treatment of hypoactive sexual desire disorder (HSDD), a sexual dysfunction affecting approximately 10% of adult women. Etiologic factors include conditions or drugs that decrease brain dopamine, melanocortin, oxytocin, and norepinephrine levels and augment brain serotonin, endocannabinoid, prolactin, and opioid levels. Symptoms include lack or loss of motivation to participate in sexual activity due to absent or decreased spontaneous desire, sexual desire in response to erotic cues or stimulation, or ability to maintain desire or interest through sexual activity for at least 6 months, with accompanying distress. Treatment follows a biopsychosocial model and is guided by history and assessment of symptoms. Sex therapy has been the standard treatment, although there is a paucity of studies assessing efﬁcacy, except for mindfulness-based cognitive behavior therapy. Bupropion and buspirone may be considered off-label treatments for HSDD, despite limited safety and efﬁcacy data. Menopausal women with HSDD may beneﬁt from off-label testosterone treatment, as evidenced by multiple clinical trials reporting some efﬁcacy and short-term safety. Currently, ﬂibanserin is the only Food and Drug Administrationeapproved medication to treat premenopausal women with generalized acquired HSDD. Based on existing data, we hypothesize that all these therapies alter central inhibitory and excitatory pathways. In conclusion, HSDD signiﬁcantly affects quality of life in women and can effectively be managed by health care providers with appropriate assessments and individualized treatments.","language":"en","number":"1","urldate":"2021-12-28","journal":"Mayo Clinic Proceedings","author":[{"propositions":[],"lastnames":["Goldstein"],"firstnames":["Irwin"],"suffixes":[]},{"propositions":[],"lastnames":["Kim"],"firstnames":["Noel","N."],"suffixes":[]},{"propositions":[],"lastnames":["Clayton"],"firstnames":["Anita","H."],"suffixes":[]},{"propositions":[],"lastnames":["DeRogatis"],"firstnames":["Leonard","R."],"suffixes":[]},{"propositions":[],"lastnames":["Giraldi"],"firstnames":["Annamaria"],"suffixes":[]},{"propositions":[],"lastnames":["Parish"],"firstnames":["Sharon","J."],"suffixes":[]},{"propositions":[],"lastnames":["Pfaus"],"firstnames":["James"],"suffixes":[]},{"propositions":[],"lastnames":["Simon"],"firstnames":["James","A."],"suffixes":[]},{"propositions":[],"lastnames":["Kingsberg"],"firstnames":["Sheryl","A."],"suffixes":[]},{"propositions":[],"lastnames":["Meston"],"firstnames":["Cindy"],"suffixes":[]},{"propositions":[],"lastnames":["Stahl"],"firstnames":["Stephen","M."],"suffixes":[]},{"propositions":[],"lastnames":["Wallen"],"firstnames":["Kim"],"suffixes":[]},{"propositions":[],"lastnames":["Worsley"],"firstnames":["Roisin"],"suffixes":[]}],"month":"January","year":"2017","pages":"114–128","bibtex":"@article{goldstein_hypoactive_2017,\n\ttitle = {Hypoactive {Sexual} {Desire} {Disorder}},\n\tvolume = {92},\n\tissn = {00256196},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S0025619616305961},\n\tdoi = {10.1016/j.mayocp.2016.09.018},\n\tabstract = {The objective of the International Society for the Study of Women’s Sexual Health expert consensus panel was to develop a concise, clinically relevant, evidence-based review of the epidemiology, physiology, pathogenesis, diagnosis, and treatment of hypoactive sexual desire disorder (HSDD), a sexual dysfunction affecting approximately 10\\% of adult women. Etiologic factors include conditions or drugs that decrease brain dopamine, melanocortin, oxytocin, and norepinephrine levels and augment brain serotonin, endocannabinoid, prolactin, and opioid levels. Symptoms include lack or loss of motivation to participate in sexual activity due to absent or decreased spontaneous desire, sexual desire in response to erotic cues or stimulation, or ability to maintain desire or interest through sexual activity for at least 6 months, with accompanying distress. Treatment follows a biopsychosocial model and is guided by history and assessment of symptoms. Sex therapy has been the standard treatment, although there is a paucity of studies assessing efﬁcacy, except for mindfulness-based cognitive behavior therapy. Bupropion and buspirone may be considered off-label treatments for HSDD, despite limited safety and efﬁcacy data. Menopausal women with HSDD may beneﬁt from off-label testosterone treatment, as evidenced by multiple clinical trials reporting some efﬁcacy and short-term safety. Currently, ﬂibanserin is the only Food and Drug Administrationeapproved medication to treat premenopausal women with generalized acquired HSDD. Based on existing data, we hypothesize that all these therapies alter central inhibitory and excitatory pathways. In conclusion, HSDD signiﬁcantly affects quality of life in women and can effectively be managed by health care providers with appropriate assessments and individualized treatments.},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2021-12-28},\n\tjournal = {Mayo Clinic Proceedings},\n\tauthor = {Goldstein, Irwin and Kim, Noel N. and Clayton, Anita H. and DeRogatis, Leonard R. and Giraldi, Annamaria and Parish, Sharon J. and Pfaus, James and Simon, James A. and Kingsberg, Sheryl A. and Meston, Cindy and Stahl, Stephen M. and Wallen, Kim and Worsley, Roisin},\n\tmonth = jan,\n\tyear = {2017},\n\tpages = {114--128},\n}\n\n","author_short":["Goldstein, I.","Kim, N. N.","Clayton, A. H.","DeRogatis, L. R.","Giraldi, A.","Parish, S. J.","Pfaus, J.","Simon, J. A.","Kingsberg, S. A.","Meston, C.","Stahl, S. M.","Wallen, K.","Worsley, R."],"key":"goldstein_hypoactive_2017","id":"goldstein_hypoactive_2017","bibbaseid":"goldstein-kim-clayton-derogatis-giraldi-parish-pfaus-simon-etal-hypoactivesexualdesiredisorder-2017","role":"author","urls":{"Paper":"https://linkinghub.elsevier.com/retrieve/pii/S0025619616305961"},"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/zotero/saracatanese","dataSources":["eTsH756eicg6vxuG3"],"keywords":[],"search_terms":["hypoactive","sexual","desire","disorder","goldstein","kim","clayton","derogatis","giraldi","parish","pfaus","simon","kingsberg","meston","stahl","wallen","worsley"],"title":"Hypoactive Sexual Desire Disorder","year":2017}